Anxio

Quick links to important sections

Anxio

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anxio

Quick Facts

Property Description
Active ingredient Bromazepam
Form Tablets
Pharmacological class Benzodiazepine, CNS Depressant
Common use Anxiolytic (anti-anxiety)
Origin Synthetic

What Type of Medicine is Anxio (Bromazepam)?

Anxio is a pharmaceutical preparation that utilizes the active ingredient Bromazepam, a synthetic small molecule. Pharmacologically, it is classified as a Psycholeptic agent and belongs to the 1,4-Benzodiazepine chemical class, which defines it as a Central Nervous System (CNS) Depressant. It is intended for oral administration and is typically prescribed as a single-ingredient product in the dosage form of tablets.

The classification of Bromazepam as an anxiolytic and CNS depressant is recognized for its pharmacological properties. The compound is clinically characterized by an intermediate duration of action, distinguishing it from both rapid-onset and very long-acting benzodiazepine agents. The substance is also a regulated and controlled agent.

Anxio's Composition and Chemical Identity

The medicinal identity of Anxio is based exclusively on Bromazepam, which is combined with solid excipients (tableting agents). This compound belongs to a family of agents that includes structurally related benzodiazepines, such as Diazepam and Clonazepam, highlighting a shared mechanism of action. The main action of this compound is defined by its ability to exert anxiolytic effects.

Understanding the General Purpose of Anxio


The general therapeutic purpose of this medication is derived from its ability to exert a calming effect by utilizing its anxiolytic properties. It is intended for the management of states characterized by excessive emotional tension, anxiety, and restlessness, consistent with its function as a CNS depressant. The intended benefit is the restoration of emotional equilibrium, supporting patients experiencing psychological distress and facilitating a state of general relaxation.

Regulatory References

  1. European Medicines Agency (EMA)
  2. National registers of authorised medicines (EMA)
  3. NIH MedlinePlus Drug Information

What side effects are possible with Anxio?

The official safety profile for Anxio (Bromazepam) is structured around common central nervous system (CNS) effects, serious risks, and constraints for specific populations, as documented in regulatory texts.

Adverse Reaction Scope

Category Regulatory Terminology Includes
Most Common Effects Drowsiness, sedation, dizziness, loss of coordination (ataxia), and memory impairment (amnesia). These effects are often most pronounced when starting treatment.
System-Organ Classes Effects are listed under Nervous System Disorders, Psychiatric Disorders (including dependence and paradoxical reactions), Vascular Disorders (e.g., hypotension), and Skin and Subcutaneous Tissue Disorders (e.g., rash).
Serious Adverse Reactions Regulatory agencies cite the risks of physical dependence, abuse, and misuse. Abrupt cessation can result in severe withdrawal reactions, including potentially life-threatening symptoms such as seizures. Concomitant use with other CNS depressants carries the risk of profound sedation, respiratory depression, coma, and death.

Safety Constraints and Patterns

Population-Specific Safety: Special caution is noted for older adults due to increased susceptibility to dose-related effects like falls. The medicine is contraindicated in conditions such as severe hepatic insufficiency, severe respiratory insufficiency, and Myasthenia Gravis.

Duration Pattern: The official safety data explicitly links the risk of dependence to the dose and duration of treatment.

The official safety information structures the risk profile by categorizing the most frequent, expected CNS effects separately from the serious, often duration-dependent risks like dependence and severe co-medicinal interactions. This framework explicitly outlines critical safety constraints for vulnerable populations and pre-existing conditions, delineating the boundaries of use as defined in governmental regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Anxio (Bromazepam) results in an excessive extension of its core pharmacological effect: Central Nervous System (CNS) depression. Documented overdose presentations typically range from mild symptoms, such as somnolence (drowsiness), lethargy, ataxia (impaired coordination), and confusion, to more profound states like diplopia and hypotonia. Isolated ingestion is rarely life-threatening, but the risk of severe outcome is significantly increased when co-ingested with other CNS depressants, such as alcohol or opioids.


Severe Manifestations and Emergency Actions

Severe overdose may lead to life-threatening complications, including profound respiratory depression (slowed or shallow breathing), hypotension (low blood pressure), and coma. Immediate medical attention must be sought for any suspected overdose. Contact emergency services without delay if the patient exhibits difficulty breathing, extreme sleepiness, or loss of consciousness, as this action is explicitly mandated by regulatory guidance.

Management is centered on symptomatic and supportive treatment, which includes the maintenance of a patent airway and continuous monitoring of vital signs. While Flumazenil is noted as an antagonist, its use is often restricted in a clinical setting due to regulatory cautions against precipitating seizures. Official labeling notes that elderly patients and children are more susceptible to the severe effects of CNS depression and require close observation.

Therapeutic Uses of Anxio

What Anxio Treats: Main Uses and Benefits

This medication is commonly applied across domains where additional symptomatic support is needed for managing excessive anxiety. The use is generally focused on conditions where symptoms become intense, disruptive, or severe. Anxio is relevant for easing symptoms associated with pathological anxiety disorders, states of anxiety neurosis, and severe emotional tension. It is relevant for easing somatic symptoms like agitation and restlessness, and may assist with managing anxiety-driven insomnia.

This approach supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable. The application of this medication is relevant when short-term symptomatic assistance is needed, contributing to improved comfort during periods of heightened symptoms.

“It provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability.”

Quick Fact: Support for Symptoms of Nervous Tension
Primary Focus Pathological anxiety and neurotic tension
Symptom Category Tension and Restlessness
Context of Use Acute or severe symptomatic episodes
Patient Benefit Supports stability and eases distress

Regulatory References

  1. Health Canada Product Monograph on Bromazepam

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Anxio

The following rules describe the official population eligibility and non-eligibility information based strictly on governmental regulatory documents.

Category Official Regulatory Statement
Populations for whom use is contraindicated Anxio is formally prohibited for patients with known hypersensitivity to the medicine or other benzodiazepines. Use is strictly contraindicated in patients with severe respiratory insufficiency, severe hepatic insufficiency, myasthenia gravis, and sleep apnea syndrome.
Age-related eligibility rules The medicine is not recommended for children and adolescents under 18 years as safety and efficacy are not established. Older adults (geriatric patients) are eligible but must receive a reduced initial dose.
Condition-specific eligibility rules Severe hepatic insufficiency is a contraindication. Impaired renal function and chronic pulmonary insufficiency require the use of special caution and, where necessary, the lowest possible dose.
Pregnancy and lactation eligibility status Use is not recommended during pregnancy or breastfeeding due to potential risks to the fetus and the excretion of the substance into breast milk.
Eligibility-related restrictions Extreme caution is mandated for patients with a medical history of alcohol or drug abuse due to the higher risk of developing dependence.

Connection to the overall eligibility profile

Regulatory documents establish strict population boundaries for Anxio primarily through a comprehensive list of absolute contraindications targeting severe organ and neuromuscular impairment. Eligibility is further constrained by explicit restrictions and warnings for the pediatric population, older adults, and individuals with a history of substance abuse.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory information defines the interaction profile of Anxio (Bromazepam) through two primary classifications: pharmacodynamic reinforcement and pharmacokinetic alteration.

Pharmacodynamic Interactions and Restrictions

Co-administration with other substances that also depress the Central Nervous System (CNS) is officially documented to enhance side effects, particularly sedation and cardio-respiratory depression. The highest official risk warnings are associated with alcohol and opioid medicines; their concomitant use is generally restricted or should be avoided due to the documented risk of severe respiratory depression, coma, and death. This restriction also applies to other CNS depressants, including antipsychotics, antidepressant agents, and sedative H1-antihistamines.

Pharmacokinetic and Exposure-Altering Interactions

Anxio's clearance may be significantly altered by medicines that inhibit its hepatic metabolism. Substances classified as strong CYP3A4 inhibitors are documented to increase the plasma levels of bromazepam. Specific pharmacokinetic interactions include Cimetidine and Fluvoxamine, which cause a formally documented reduced clearance and prolonged elimination half-life. Additionally, regulatory documents note that special caution is required in patients with mild-to-moderate hepatic impairment, as their condition may contribute to hepatic encephalopathy and heighten interaction effects due to impaired metabolism.

Mechanism of Action

Anxio is a small molecule that selectively targets and modulates the GABAA receptor system within the central nervous system (CNS). Its primary mode of action involves positive allosteric modulation (PAM). Specifically, Anxio non-competitively binds to a recognition site located at the interface of the alpha1 and gamma2 subunits of the GABAA pentameric structure. This binding induces a conformational change in the receptor complex, which increases the receptor's affinity for endogenous GABA. The physiological consequence of this allosteric interaction is a measurable increase in the frequency of chloride channel opening. The influx of negatively charged chloride ions enhances the resting membrane potential, consequently contributing to an overall increase in inhibitory tone across the neuronal network. This downstream mechanistic cascade results in the stabilization of the cellular environment by reducing the cell's responsiveness to excitatory stimuli and ultimately promoting hyperpolarization of the neuronal membrane. This focused interaction explains the modulation of cellular signaling within the targeted neural circuits.

Dosage and Administration Information

How to Use Anxio (Bromazepam) in Clinical Practice

This section outlines the principles for the administration and dosing of Anxio (Bromazepam). All instructions are strictly descriptive of the established use protocol and do not include clinical advice or information on therapeutic effects.

Official Administration and Dosage

Anxio is administered via the Oral route and is commonly available as Tablets in strengths such as 1.5 mg, 3 mg, and 6 mg.

Usage Parameter Guideline
Dose Initiation Start with the lowest effective dose (e.g., 1.5 mg to 3 mg) and gradually increase to the optimum level.
Adult Dosing The typical daily dose for outpatients is in the range of 3 mg to 18 mg; this is typically taken in divided doses (2 to 3 times per day).
Max Dose (Severe Cases) Doses up to 60 mg daily may be considered in severe, often hospitalized cases.
Timing Absorption is nearly complete when the medicine is taken in a fasting state.

Duration and Specific Population Rules

Anxio is intended for short-term use only, and the duration of treatment must not exceed a specified maximum period.

  • Total Course Duration: The treatment, including the period required for dose reduction, should generally not exceed 8 to 12 weeks.
  • Discontinuation: The dose must always be tapered off gradually when stopping the medication.
  • Older Adults: A reduced dose is mandatory, often recommended not to exceed half the standard adult dose due to increased sensitivity.
  • Impaired Function: The lowest possible dose is advised for patients with mild to moderate hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anxio (Bromazepam)


Evidence for Use in Pathological Anxiety Disorders

The core clinical evidence for bromazepam was gathered primarily through short-term randomized controlled trials (RCTs) and supporting systematic reviews. These studies was evaluated in research exploring how symptoms change over time, typically lasting six to eight weeks. The research included adults diagnosed with conditions like pathological anxiety or anxiety neurosis. Studies monitored how symptoms evolved in the observed populations by measuring changes in anxiety symptom severity using established clinical scales.

The findings from these studies describe patterns observed in the studies related to temporary changes in anxiety symptom scores and outcomes related to systemic or functional imbalance, such as restlessness and agitation, when evaluated against a placebo condition. This evidence contributes to research exploring symptom patterns and how patients reported their experience during the study period. However, the evidence is limited, particularly regarding long-term study periods.


Evidence for Use in Severe Emotional Tension and Acute Reactions

Bromazepam was studied for its role in managing conditions associated with acute or disruptive episodes, such as severe emotional tension and acute stress reactions. The research conducted during periods of increased symptom activity often involved short-term RCTs, with the focus being on the measurement of symptom changes over defined time intervals, sometimes only days or one to two weeks.

In these acute settings, research examined how quickly individuals experienced a change in outcomes describing episodic or acute changes and the severity of physical discomfort. Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to changes in acute anxiety symptoms and tension.


Duration of Evidence and Long-Term Follow-up

The bulk of the clinical evidence available for bromazepam is centered on short-term study periods, typically ranging from a few weeks to two to three months. Research has explored the response during the initial phase of treatment, but long-term effects are not fully established. Limited information is available from extended-duration studies evaluating the sustained maintenance of symptom measurements over periods longer than 12 weeks. Results apply only to the populations studied and the specific short follow-up durations were limited.


What the Research Record Indicates is Still Uncertain

The overall evidence landscape indicates several areas where research is still emerging or where data are incomplete. One major limitation is the absence of large-scale, long-term randomized controlled trials necessary to characterize outcomes and safety patterns beyond a few months of use. Furthermore, comparative evidence is limited in some areas, particularly concerning studies examining bromazepam against some newer, non-benzodiazepine treatments for anxiety.

Key Studies & References

  1. Bromazepam Monograph (Therapeutic Uses, Clinical Trials, Adverse Reactions)
  2. Benzodiazepine Use for Anxiety Disorders: A Review of the Clinical Evidence
  3. Management of Generalised Anxiety Disorder: NICE Clinical Guideline [CG113]

Frequently Asked Questions (FAQ)

Common questions about Anxio (FAQ)


Q: How is Anxio different from other similar treatments?

Official information classifies Anxio as a 1,4-Benzodiazepine and a Central Nervous System (CNS) Depressant. It is described as having an intermediate duration of action, which distinguishes it from both very short-acting and very long-acting agents in the same chemical class. The compound shares a similar structure and mechanism with other benzodiazepines like Diazepam and Clonazepam.


Q: What kind of foods or drinks should be avoided while taking Anxio?

Regulatory documents state that alcohol is generally restricted or should be avoided entirely due to the documented risk of profound sedation and severe respiratory depression. Separate administration instructions note that absorption is nearly complete when the medicine is taken in a fasting state.


Q: Is Anxio suitable for people over the age of 65?

Older adults are included in the official population guidance, but regulatory documents note an increased susceptibility to dose-related effects like dizziness and falls. Due to this increased sensitivity, official guidance describes that a reduced initial dose is required, often specified not to exceed half the standard adult dose.


Q: Is Anxio used to treat conditions other than anxiety?

The medicine is primarily indicated for managing conditions associated with anxiety, such as pathological anxiety, severe emotional tension, and acute stress reactions. However, some regulatory documents also include indications for its short-term use in managing insomnia and as a pre-medication for minor surgical or diagnostic procedures where anxiety is a factor.


Q: Can Anxio change your mood or personality?

Official safety documents list effects under the category of Psychiatric Disorders which include dependence, as well as paradoxical reactions such as aggressiveness, agitation, and inappropriate behavior. Personality changes are also cited as a potential, though rare, adverse reaction in the safety data.


Q: Is Anxio often used in combination with other mental health treatments?

Regulatory documents explicitly warn of pharmacodynamic reinforcement, meaning enhanced side effects, when Anxio is used with other CNS depressants, including antipsychotic and antidepressant agents. This warning highlights the need for extreme caution when this medicine is administered alongside other CNS depressants, which is documented to carry an increased risk of profound sedation.


Q: Are there specific times of day Anxio is generally recommended to be taken?

Official guidelines describe that the typical daily dose is usually taken in divided doses, often two to three times per day. The patient's prescribing doctor determines the most appropriate timing to manage symptoms effectively throughout the day.


Q: Can Anxio interact with cold and flu medications?

Regulatory information warns that using Anxio with substances that also depress the Central Nervous System (CNS) can enhance side effects like sedation. This caution explicitly applies to sedative H1-antihistamines, which are active components found in some over-the-counter cold and flu preparations.


Q: Does Anxio affect sleep quality?

As a CNS depressant, Anxio commonly causes drowsiness and sedation. Its safety profile also lists more specific effects on sleep, such as sleep disorder and nightmares, as possible adverse reactions. The medicine is contraindicated for people with pre-existing conditions like sleep apnea syndrome.


Q: What is the official guidance regarding Anxio use for people with a history of seizures?

Regulatory documents contain specific warnings regarding use in persons with convulsive disorders, such as epilepsy. They state that an increase in the frequency and/or severity of existing seizures may occur. Official guidance describes that caution is required in this population.


Q: Why is it important to continue taking Anxio even if you start to feel better?

Official prescribing protocol requires that the dose must always be tapered off gradually when stopping the medication, even after short-term use. This gradual reduction is necessary to avoid severe withdrawal reactions, which are documented to include potentially life-threatening symptoms such as seizures.


Q: How long does it typically take for Anxio to start working?

Pharmacokinetic data from regulatory sources provides information on how quickly the medicine enters the bloodstream. Peak plasma levels of Anxio are generally reached between 0.5 to 4 hours after the tablets are taken orally, and the medicine's activity is expected to begin within this time frame.


Q: What happens if a dose of Anxio is missed?

Official guidance describes that if a dose is missed, the dose is taken as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the missed dose is skipped entirely. Regulatory instructions emphasize that doubling the dose to make up for the one that was missed is not the correct procedure.


Q: How long does Anxio stay in your system after the last dose?

Regulatory pharmacokinetic studies indicate that Anxio has an elimination half-life of about 17 hours, though this can range from 11 to 22 hours depending on the individual. This is the time it takes for half of the dose to be cleared from the body.


Q: What should be done if an unusual side effect is experienced while on Anxio?

Regulatory guidance describes that all unexpected or unusual effects are reported to a healthcare provider. In countries like the UK, national agencies operate specific systems, such as the Yellow Card scheme, for formally documenting and monitoring adverse drug reactions.


Q: Can Anxio affect sexual function?

Official side effect lists for this class of medicine include changes in sexual desire (libido) as a potential effect. This is a documented potential effect.


Q: Is it true that Anxio can cause vivid dreams?

Official safety data for the medicine lists nightmares as a possible, though rare, adverse reaction under the category of Psychiatric Disorders.


Q: What is the risk of suicidal thoughts while taking Anxio, according to official sources?

Official safety documents list suicidal thoughts or behaviour as potential rare adverse reactions under the category of Psychiatric Disorders for this medicine. Official documents state that these are serious adverse reactions which require immediate notification to a healthcare provider if observed.


Q: Can Anxio affect blood sugar levels?

Official safety documents list potential effects on laboratory parameters as part of the known adverse reactions. A rare adverse reaction documented for this medicine is blood glucose decreased.


Q: Can Anxio cause blurred vision?

Official safety data lists blurred vision as a potential adverse reaction under the category of Eye Disorders.


Q: What is the difference in effect between a low dose and a high dose of Anxio?

Pharmacological texts note that in low doses, the medicine is intended to selectively reduce tension and anxiety. In high doses, the additional properties of sedation and muscle-relaxation become more apparent.


Q: What are the known effects of Anxio on the heart rhythm?

Official safety documents list potential cardiac-related effects as possible adverse reactions. These include palpitations, cardiac disorder, tachycardia (a faster than normal heart rate), and cardiac arrest.


Q: Can Anxio cause dry mouth?

Official safety data lists dry mouth as a possible adverse reaction.

How should Anxio be stored and disposed of?

How to Store and Dispose of Anxio (Bromazepam) Tablets

The storage and disposal of Anxio tablets must adhere strictly to the conditions specified in the official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (typically 15 C to 30 C).
Protection Protect from moisture and heat. The product must not be frozen.
Container Keep the medicine in its original container.
Child Safety Keep tablets out of the reach and sight of children.

Official Disposal Instructions

Unused or expired Anxio tablets must not be discarded in household trash or wastewater (sinks or toilets). Disposal must follow local pharmaceutical waste regulations, which typically involves returning the medicine to a pharmacy or a designated community drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anxio found in:

A-Z Index: